[go: up one dir, main page]

PE20050484A1 - Composicion farmaceutica de liberacion sostenida - Google Patents

Composicion farmaceutica de liberacion sostenida

Info

Publication number
PE20050484A1
PE20050484A1 PE2004001037A PE2004001037A PE20050484A1 PE 20050484 A1 PE20050484 A1 PE 20050484A1 PE 2004001037 A PE2004001037 A PE 2004001037A PE 2004001037 A PE2004001037 A PE 2004001037A PE 20050484 A1 PE20050484 A1 PE 20050484A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
sustained release
release pharmaceutical
alkyl
dioxino
Prior art date
Application number
PE2004001037A
Other languages
English (en)
Inventor
Eric Joel Benjamin
Wendy Ann Dulin
Yanning Lin
Kai Zhuang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34572826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050484(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20050484A1 publication Critical patent/PE20050484A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I DONDE R1 Y R2 SON H, ALQUILO C1-C6, FENILO, BENCILO, ENTRE OTROSR3 ES H, OH, HALOGENO, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, ENTRE OTROS; n ES 0-6; Z ES H, OH, ALQUILO C1-C6, ENTRE OTROS. TAMBIEN REFERIDA A UNA FORMULACION EN LA QUE SON COMPUESTOS PREFERIDOS: 2-[(BENCILAMINO)-METIL]-2,3,8,9-TETRAHIDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONA Y S-2-[(BENCILAMINO)-METIL]-2,3,8,9- TETRAHIDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONA. DICHOS COMPUESTOS SON UTILES EN EL SINDROME DE TOURET, ENFERMEDAD DE PARKINSON, ESQUIZOFRENIA, ENTRE OTROS
PE2004001037A 2003-10-29 2004-10-28 Composicion farmaceutica de liberacion sostenida PE20050484A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51531503P 2003-10-29 2003-10-29

Publications (1)

Publication Number Publication Date
PE20050484A1 true PE20050484A1 (es) 2005-10-13

Family

ID=34572826

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001037A PE20050484A1 (es) 2003-10-29 2004-10-28 Composicion farmaceutica de liberacion sostenida

Country Status (21)

Country Link
US (5) US20050095292A1 (es)
EP (1) EP1675583B1 (es)
JP (1) JP5547865B2 (es)
KR (1) KR101409724B1 (es)
CN (2) CN102335116A (es)
AR (1) AR046222A1 (es)
AU (1) AU2004286855B2 (es)
BR (1) BRPI0415953B8 (es)
CA (1) CA2543045C (es)
ES (1) ES2405404T3 (es)
GT (1) GT200400218A (es)
IL (1) IL174958A (es)
MX (1) MXPA06004752A (es)
NO (1) NO20062004L (es)
PA (1) PA8616201A1 (es)
PE (1) PE20050484A1 (es)
RU (1) RU2376988C2 (es)
SG (1) SG147450A1 (es)
TW (1) TW200517106A (es)
WO (1) WO2005044262A1 (es)
ZA (1) ZA200603409B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200517106A (en) 2003-10-29 2005-06-01 Wyeth Corp Sustained release pharmaceutical compositions
US8858993B2 (en) 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
US20070048377A1 (en) * 2005-08-26 2007-03-01 Ali Rajabi-Siahboomi Drug compositions containing controlled release hypromellose matrices
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
NZ608196A (en) 2008-08-19 2014-09-26 Xenoport Inc Prodrugs of methyl, hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
RU2561681C2 (ru) * 2008-12-22 2015-08-27 Новартис Аг Схема приема агониста рецептора s1p
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
LT2661261T (lt) 2011-01-07 2019-10-25 Novartis Ag Imunosupresantų kompozicijos
US10137093B2 (en) 2011-08-16 2018-11-27 Cardiora Pty Ltd. Milrinone controlled-release formulation
WO2014031844A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014031892A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
WO2015035184A1 (en) 2013-09-06 2015-03-12 Xenoport, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
AU2015372434B2 (en) 2014-12-22 2018-10-04 Baker Heart and Diabetes Institute Method of treatment
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
BR112019027398A2 (pt) 2017-06-21 2020-07-07 Minerva Neurosciences, Inc. formas de dosagem orais de liberação controlada gastrorresistente
JP6983139B2 (ja) * 2017-11-27 2021-12-17 信越化学工業株式会社 固形製剤用組成物並びに固形製剤及びその製造方法
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
CA3180743A1 (en) * 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation
TWI841545B (zh) * 2018-12-12 2024-05-11 日商田邊三菱製藥股份有限公司 耐胃性控制釋放經口劑型
CN113559074B (zh) * 2020-06-28 2023-04-21 海创药业股份有限公司 一种喹啉类化合物缓释片及其制备方法
CN116549406B (zh) * 2023-05-23 2023-12-19 北京丰科睿泰医药科技有限公司 一种盐酸曲唑酮缓释片剂
WO2025240494A1 (en) 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
JP2687448B2 (ja) * 1988-06-22 1997-12-08 大正製薬株式会社 イブプロフェン徐放性製剤
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
US4988679A (en) * 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
EP0594593A1 (en) 1990-03-15 1994-05-04 PHARMACIA & UPJOHN COMPANY Therapeutically useful heterocyclic indole compounds
JP2600978B2 (ja) * 1990-05-25 1997-04-16 日産自動車株式会社 サスペンションのアッパリンク支持部構造
US5128366A (en) * 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
US5168387A (en) * 1990-12-11 1992-12-01 Central Glass Company, Limited Variable light transmittance device
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5166367A (en) 1991-06-21 1992-11-24 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5189171A (en) 1991-06-21 1993-02-23 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5126366A (en) 1991-06-21 1992-06-30 American Home Products Corporation Aminophenoxyalkyl derivatives of benzodioxan
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5235055A (en) * 1992-09-02 1993-08-10 American Home Products Corporation Antipsychotic quinoline derivatives of benzodioxanmethylamine
US5245051A (en) * 1992-09-03 1993-09-14 American Home Products Corporation Antipsychotic chroman derivatives of benzodioxanmethylamine
DE69325698T2 (de) 1992-12-21 2000-01-27 Duphar International Research B.V., Weesp Enzymatisches Verfahren zur stereoselektiven Herstellung einem Enantiomer aus einem hetero bicyclischen Alkohols
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
EP0866707A1 (en) * 1995-12-01 1998-09-30 Janssen Pharmaceutica N.V. Cisapride sustained release
JPH09315969A (ja) * 1996-05-24 1997-12-09 Taiyo Yakuhin Kogyo Kk イブジラスト含有徐放性医薬品組成物及びその製造方法
GB9627005D0 (en) 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents
GB9704948D0 (en) 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
TW587938B (en) 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6417177B1 (en) * 1999-07-13 2002-07-09 Alpha Research Group, Llc Chloroquine derivatives for the treatment of Parkinson's disease
RU2256454C2 (ru) * 1999-12-03 2005-07-20 Полишем С.А. Способы получения фармацевтических композиций алкалоидов спорыньи с пролонгированным действием, характеризующихся улучшенной биодоступностью, и содержащие указанные алкалоиды композиции
EP1235570A2 (en) 1999-12-10 2002-09-04 Wyeth Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics
US6350773B1 (en) * 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
US6524618B1 (en) * 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
TW200517106A (en) * 2003-10-29 2005-06-01 Wyeth Corp Sustained release pharmaceutical compositions
TW200811182A (en) 2006-05-25 2008-03-01 Wyeth Corp Oxindoledioxans, synthesis thereof, and intermediates thereto

Also Published As

Publication number Publication date
AU2004286855B2 (en) 2011-04-21
US20180344695A1 (en) 2018-12-06
ZA200603409B (en) 2010-10-27
NO20062004L (no) 2006-07-07
CN102335116A (zh) 2012-02-01
CA2543045A1 (en) 2005-05-19
KR101409724B1 (ko) 2014-06-19
CN1874767A (zh) 2006-12-06
BRPI0415953B8 (pt) 2021-05-25
AR046222A1 (es) 2005-11-30
MXPA06004752A (es) 2006-07-05
KR20060110281A (ko) 2006-10-24
US20050095292A1 (en) 2005-05-05
US10463648B2 (en) 2019-11-05
IL174958A0 (en) 2008-04-13
US20230061743A1 (en) 2023-03-02
BRPI0415953B1 (pt) 2018-12-26
JP5547865B2 (ja) 2014-07-16
BRPI0415953A (pt) 2007-01-02
EP1675583A1 (en) 2006-07-05
US11179369B2 (en) 2021-11-23
WO2005044262A1 (en) 2005-05-19
AU2004286855A1 (en) 2005-05-19
RU2376988C2 (ru) 2009-12-27
US10292966B2 (en) 2019-05-21
US20180193311A1 (en) 2018-07-12
TW200517106A (en) 2005-06-01
GT200400218A (es) 2005-06-06
ES2405404T3 (es) 2013-05-31
HK1089394A1 (en) 2006-12-01
IL174958A (en) 2012-08-30
JP2007509970A (ja) 2007-04-19
US20200138781A1 (en) 2020-05-07
CA2543045C (en) 2013-12-17
PA8616201A1 (es) 2005-05-24
EP1675583B1 (en) 2013-02-27
RU2006118321A (ru) 2007-12-10
SG147450A1 (en) 2008-11-28

Similar Documents

Publication Publication Date Title
PE20050484A1 (es) Composicion farmaceutica de liberacion sostenida
NO20052914L (no) Terapeutiske forbindelser
NO20033145L (no) Purinderivater som purinergiske reseptorantagonister
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
PE20090042A1 (es) Analogos de ciclopamina
AR020551A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos.
PE20050476A1 (es) Compuestos de pirrol y pirazol
SE0104334D0 (sv) Therapeutic agents
ATE249213T1 (de) Pentafluorobenzensulfonamiden und analoge
MXPA05008600A (es) Compuestos para el tratamiento de desordenes metabolicos.
SE0201659D0 (sv) Modified release pharmaceutical formulation
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
NO20054787L (no) Indenderivater som farmasotiske midler
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
ATE336230T1 (de) Orale pharmazeutische zusammensetzung und verfahren zu ihrer herstellung
MA28286A1 (fr) Dérivés de 1-N-phenyl-amino-1H-imidazole et compositions pharmaceutiques les contenant
WO2006110884A3 (en) 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists
AR053559A1 (es) Compuestos derivados antibacterianos de 2,4' -dihidroxifenilo 3',5-disustituidos y metodos relacionados
PE20061083A1 (es) Composicion farmaceutica que comprende benzoxazoles sustituidos
SV2006002089A (es) Nuevos imidazoles ref. docket 18699 (pc26195a)
TR200200550T2 (tr) Piruvat dehidrojenaz aktivitesini yükselten ikameli n-fenil 2-hidroksi -2- metil -3,3,3- triflüoropropanamid türevleri.

Legal Events

Date Code Title Description
FC Refusal